

PERSONAL INFORMATION **Eva Baecklund**WORK EXPERIENCE

---

- 2004- 2016 **Senior physician/consultant in rheumatology, Department of rheumatology Uppsala University Hospital (Sweden)**
- 2016- 2021 **Ass professor in rheumatology/senior lecturer combined with position as senior physician/consultant**  
Department of Medical Sciences, Uppsala University (Sweden)
- 2021- Present **Senior researcher, Department of Medical Sciences**  
Uppsala University (Sweden)

EDUCATION AND TRAINING

---

- 1983 **Medical degree/physicians exam**  
Uppsala University (Sweden)
- 1987 **Medical licensure**  
( )
- 1993 **Registered specialist in internal medicine**  
( )
- 1995 **Registered specialist in rheumatology**  
( )
- 2011 **Docentship/Associate professor in rheumatology**  
Uppsala University (Sweden)

ADDITIONAL INFORMATION

---

- Expertise** Rheumatic diseases and malignancy risks, especially the association with lymphoma.  
Drug safety of anti-rheumatic therapy.  
These areas have been the focus of my research and the work within ARTIS (Anti-Rheumatic Therapy in Sweden, a study group within the Swedish Rheumatology Association focused on different aspects of anti-rheumatic therapy including safety). I was during many years PI of the work with national safety guidelines of anti-rheumatic therapy within the Swedish Rheumatology Association and member of the group working with national RA treatment guidelines.
- Publications** Published manuscripts including reviews: 73  
Book chapters: 5  
Other publications indexed in Pub Med (Eva Baecklund member of study groups): 32
- Publications Eva Baecklund:  
1. Baecklund E, Ekbohm A, Sparen P, Feltelius N, Klareskog L.  
Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control

- study. *British Medical Journal* 1998;317:180-1.
2. Bjornadal L, Baecklund E, Yin L, Granath F, Klareskog L, Ekbom A. Decreasing mortality in patients with rheumatoid arthritis: results from a large population based cohort in Sweden 1964-95. *J Rheumatology* 2002; 29:906-12.
  3. Ekstrom K, Hjalgrim H, Brandt L, Baecklund E, Klareskog L, Ekbom A, Askling J. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. *Arthritis Rheum* 2003; 48:963-70.
  4. Baecklund E, Sundstrom C, Ekbom A, Catrina AI, Biberfeld P, Feltelius N, Klareskog L. Lymphoma subtypes in patients with rheumatoid arthritis: Increased proportion of diffuse large B-cell lymphoma. *Arthritis Rheum* 2003; 48:1543-50.
  5. Forsman A, Uzameckis D, Ronnblom L, Baecklund E, Aleskog A, Bindra A, Pipkorn R, Lejniece S, Koziera S, Murovska M, Blomberg J. Single-tube nested quantitative PCR: a rational and sensitive technique for detection of retroviral DNA. Application to RERV-H/HRV-5, and confirmation of its rabbit origin. *J Virological Methods* 2003; 111: 1-11.
  6. Baecklund E, Askling J, Rosenquist R, Ekbom A, Klareskog L. Rheumatoid arthritis and malignant lymphomas. *Curr Opin Rheumatol* 2004;16:254-261.
  7. Askling J, Fored CM, Brandt L, Baecklund E, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. *Ann Rheum Dis* 2005; 64:1421-6.
  8. Askling J, Klareskog L, Hjalgrim H, Baecklund E, Bjorkholm M, Ekbom A. Do steroids increase lymphoma risk in polymyalgia rheumatica/ giant cell arthritis. *Ann Rheum Dis* 2005; 64:1765-8.
  9. Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. *Ann Rheum Dis* 2005; 64:1414-20.
  10. Askling J, Fored CM, Brandt L, Baecklund E, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumour necrosis factor antagonists in Sweden. *Arthritis Rheum* 2005; 52:1986-92.
  11. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, Catrina AI, Rosenquist R, Feltelius N, Sundstrom C, Klareskog L. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. *Arthritis Rheum* 2006; 54:692-701.
  12. Smedby KE, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors and lymphoma characteristics. *Cancer Epidemiol Biomarkers Prev* 2006;15:2069-77.
  13. Baecklund E, Backlin C, Iliadou A, Granath F, Ekbom A, Amini R-M, Feltelius N, Enblad G, Sundstrom C, Klareskog L, Askling J, Rosenquist R. Characteristics of diffuse large B-cell lymphomas in rheumatoid arthritis. *Arthritis Rheum* 2006; 54:3774-378.
  14. Askling J, Fored CM, Brandt L, Baecklund E, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA-patients treated with TNF-antagonists. *Ann Rheum Dis* 2007; 66:1339-44.
  15. Sokka T, Kautiainen H, ...Baecklund E, et al. QUEST-RA: Quantitative clinical assessment of patients with rheumatoid arthritis seen in standard clinical care in 15 countries. *Ann Rheum Dis* 2007;66:1491-96.
  16. Baecklund E, Natkunam Y, Backlin C, Askling J, Ekbom A, Feltelius N, Klareskog L, Enblad G, Lossos I, Levy R, Sundstrom C, Rosenquist R. Expression of the human germinal-center associated lymphoma (HGAL) protein in diffuse large B-cell lymphomas in patients with rheumatoid arthritis. *Br J Haematol* 2008;141:69-72.
  17. Ekstrom Smedby K, Askling J, Mariette X, Baecklund E. Autoimmune and inflammatory disorders and risk of malignant lymphomas-an update. *J Intern Med* 2008;264 (6):514-27.
  18. Askling J, Baecklund E, Granath F, Geborek P, Fored M, Backlin C, Bertilsson L, Coster L, Jacobsson LT, Lindblad S, Lysholm J, Rantapaa-Dahlqvist S, Saxne T, van Vollenhoven R, Klareskog L, Feltelius N. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas. Relative risks and time trends in the Swedish Biologics Register. *Ann Rheum Dis* 2009;68:648-53.
  19. Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, et al. Cancer risk in patients with RA treated with anti-TNF: does the risk change with time since treatment start? *Arthritis Rheum* 2009;60:3180-89.
  20. Sokka T, Kautiainen H, Pincus T, ...Baecklund E, et al. Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. *Ann Rheum Dis* 2009;68:1662-72.

21. Hellgren K, Iliadou A, Rosenquist R, Feltelius N, Backlin C, Enblad G, Askling J, Baecklund E. Rheumatoid arthritis, treatment with corticosteroids, and risk of malignant lymphomas. *Ann Rheum Dis* 2010;69:654-9.
22. Hellgren K, Smedby KE, Feltelius N, Baecklund E, Askling J. Do rheumatoid arthritis and lymphoma share risk factors? A comparison of lymphoma and cancer risks before and after the diagnosis of rheumatoid arthritis. *Arthritis Rheum.* 2010 May;62(5):1252-8.
23. Sokka T, Kautiainen H, Pincus T, Verstappen SM, Aggarwal A, Alten R, Andersone D, Badsha H, Baecklund E, et al. Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study. *Arthritis Res Ther.* 2010;12 (2):R42.
24. Nordmark G, Kristjansdottir G, Theander E, Appel S, Eriksson P, Vasaitis L, Kvarnstrom M, Delaleu N, Lundmark P, Lundmark A, Sjowall C, Brun JG, Jonsson MV, Harboe E, Goransson LG, Johnsen SJ, Soderkvist P, Eloranta ML, Alm G, Baecklund E, Wahren-Herlenius M, Omdal R, Ronnblom L, Jonsson R, Syvanen AC. Association of EBF1, FAM167A(C8orf13)-BLK and TNFSF4 gene variants with primary Sjogren's syndrome. *Genes Immun* 2011;12:100-9.
25. Simard JF, Arkema EV, Sundstrom A, Geborek P, Saxne T, Baecklund E, Coster L, Dackhammar C, Jacobsson L, Feltelius N, Lindblad S, Rantapaa-Dahlqvist S, Klareskog L, van Vollenhoven RF, Neovius M, Askling J. Ten years with biologics: to whom do data on effectiveness and safety apply? *Rheumatology (Oxford)* 2011;50:204-13.
26. Simard JF, Baecklund E, Kinch A, Brattstrom C, Ingvar A, Molin D, Adami J, Fernberg P, Wilczek H, Ekblom A, Smedby KE. Pediatric organ transplantation and risk of premalignant and malignant tumors in Sweden. *Am J Transplant.* 2011 Jan;11(1):146-51.
27. Baecklund E, Backlin C, Mansouri M, Klareskog L, Askling J, Nyman Iliadou A, Enblad G, Lossis IS, Natkuman Y, Rosenquist R. LMO2 protein expression predicts survival in rheumatoid arthritis patients with diffuse large B-cell lymphoma. *Leuk Lymphoma.* 2011 Jun;52(6):1146-9.
28. Lofstrom B, Backlin C, Pettersson T, Lundberg IE, Baecklund E. Expression of APRIL in diffuse large B cell lymphomas from patients with systemic lupus erythematosus and rheumatoid arthritis. *J Rheumatol.* 2011;38:1891-7.
29. Theander E, Vasaitis L, Baecklund E, Nordmark G, Warfvinge G, Liedholm R, Brokstad K, Jonsson R, Jonsson MV. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndrome. *Ann Rheum Dis.* 2011 Aug;70(8):1363-8.
30. Fernberg P, Edgren G, Adami J, Ingvar A, Bellocco R, Tufveson G, Hoglund P, Kinch A, Simard JF, Baecklund E, Lindelof B, Pawitan Y, Smedby KE. Time trends in risk and risk determinants of non-Hodgkin lymphoma in solid organ transplant recipients. *Am J Transplant.* 2011 Nov;11(11):2472-82.
31. Krynitz B, Edgren G, Lindelof B, Baecklund E, Brattstrom C, Wilczek H, Smedby KE. Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008 - a swedish population-based study. *Int J Cancer.* 2013 Mar 15;132(6):1429-38.
32. Simard JF, Baecklund E, Chang ET, Baecklund E, Hjalgrim H, -Olov Adami H, Glimelius B, Smedby KE. Lifestyle factors, autoimmune disease and family history in prognosis of non-hodgkin lymphoma overall and subtypes. *Int J Cancer.* 2013 Jun 1;132(11):2659-66.
33. Baecklund E, Smedby KE, Sutton LA, Askling J, Rosenquist R. Lymphoma development in patients with autoimmune and inflammatory disorders - What are the driving forces? *Semin Cancer Biol.* 2014 Feb;24:61-70.
34. Hellgren K, Smedby KE, Backlin C, Sundstrom C, Feltelius N, Eriksson JK, Baecklund E, Askling J. Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden. *Arthritis Rheumatol.* 2014 May;66(5):1282-90.
35. Kinch A, Baecklund E, Backlin C, Ekman T, Molin D, Tufveson G, Fernberg P, Sundstrom C, Pauksens K, Enblad G. A population-based study of 135 lymphomas after solid organ transplantation: The role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival. *Acta Oncol.* 2014 May;53(5):669-79.
36. Kinch A, Cavelier L, Bengtsson M, Baecklund E, Enblad G, Backlin C, Thunberg U, Sundstrom C, Pauksens K. Donor or Recipient Origin of Posttransplant Lymphoproliferative Disorders Following Solid Organ Transplantation. *Am J Transplant.* 2014 Dec;14(12):2838-45.
37. Knight A, Hallenberg H, Baecklund E. Efficacy and safety of rituximab as maintenance therapy for relapsing granulomatosis with polyangiitis-a case series. *Clin Rheumatol.* 2014 Jun;33(6):841-8.

38. Berglund D, Kinch A, Edman E, Backlin C, Enblad G, Larsson E, Molin D, Pauksens K, Sundstrom C, Baecklund E. Expression of Intratumoral Forkhead Box Protein 3 in Posttransplant Lymphoproliferative Disorders: Clinical Features and Survival Outcomes. *Transplantation*. 2015 May;99(5):1036-42.
39. Arkema EV, Jonsson J, Baecklund E, Bruchfeld J, Feltelius N, Asklings J; on behalf of the ARTIS Study Group. Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments? *Ann Rheum Dis*. 2015 Jun;74(6):1212-7.
40. Knight A, Hjorton K, Sundstrom C, Hoglund M, Backlin C, Smedby KE, Asklings J, Baecklund E. Leukemia and Myelodysplastic Syndrome in Granulomatosis with Polyangiitis: Subtypes, Clinical Characteristics, and Outcome. *J Rheumatol*. 2015 Apr;42(4):690-4.
41. Brauner S, Zhou W, Backlin C, Green TM, Folkersen L, Ivanchenko M, Lofstrom B, Xu-Monette ZY, Young KH, Moller Pedersen L, Boe Moller M, Sundstrom C, Enblad G, Baecklund E, Wahren-Herlenius M. Reduced expression of TRIM21/Ro52 predicts poor prognosis in diffuse large B-cell lymphoma patients with and without rheumatic disease. *J Intern Med*. 2015 Sep;278(3):323-32.
42. Vasaitis L, Sundstrom C, Backlin C, Nordmark G, Baecklund E. Sporadic occurrence of non-diagnosed IgG4-related disease in lymphoma patients with a previous Sjogren's syndrome diagnosis. *Acta Oncol* 2016;55:1139-1144.
43. Hellgren K, Baecklund E, Backlin C, Sundstrom C, Smedby KE, Asklings J. Rheumatoid Arthritis and Risk of Malignant Lymphoma - Is the risk still increased? *Arthritis Rheumatol*. 2017 Apr;69(4):700-708.
44. Enblad G, Martinsson G, Baecklund E, Hesselager G, Sundstrom C, Amini RM, Hagberg H. Population-based experience on primary central nervous system lymphoma 2000-2012: the incidence is increasing. *Acta Oncol*. 2017 Apr;56(4):599-607.
45. Ramirez Sepulveda JI, Kvarnstrom M, Eriksson P, Mandl T, Norheim KB, Johnsen SJ, Hammenfors D, Jonsson MV, Skarstein K, Brun JG; DISSECT consortium, Ronnblom L, Forsblad-d'Elia H, Magnusson Bucher S, Baecklund E, Theander E, Omdal R, Jonsson R, Nordmark G, Wahren-Herlenius M. Long-term follow-up in primary Sjogren's syndrome reveals differences in clinical presentation between female and male patients. *Biol Sex Differ*. 2017 Aug 8;8(1):25
46. Mercer LK, Regierer AC, Mariette X, Dixon WG, Baecklund E, Hellgren K, Dreyer L, Hetland ML, Cordtz R, Hyrich K, Strangfeld A, Zink A, Canhao H, Hernandez MV, Tubach F, Gottenberg JE, Morel J, Zavada J, Iannone F, Asklings J, Listing J. Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. *Ann Rheum Dis*. 2017 Dec;76(12):2025-2030.
47. Frisell T, Baecklund E, Bengtsson K, Di Giuseppe D, Forsblad-d'Elia H, Asklings J; ARTIS Study group. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics. *Ann Rheum Dis*. 2018 May;77(5):650-657.
48. Baecklund E, Backlin C, Ronnelid J, Toes R, Huizinga T, Ahlin E, Asklings J, Hochberg FH, Klareskog L, Kay J, Smedby KE. Anti-cyclic citrullinated peptide antibodies, other common autoantibodies, and smoking as risk factors for lymphoma in patients with rheumatoid arthritis. *Scand J Rheumatol*. 2018 Jul;47(4):270-75.
49. Kinch A, Sundstrom C, Baecklund E, Backlin C, Molin D, Enblad G. Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation. *Leuk Lymphoma*. 2018 Jul 22:1-9.
50. Vasaitis L, Nordmark G, Theander E, Backlin C, Smedby KE, Asklings J, Ronnblom L, Sundstrom C, Baecklund E. Comparison of patients with and without pre-existing lymphoma at diagnosis of primary Sjogren's syndrome. *Scand J Rheumatol*. 2019 May;48(3):207-212.
51. Karlsson Sundbaum J, Eriksson N, Hallberg P, Lehto N, Wadelius M, Baecklund E. Methotrexate treatment in rheumatoid arthritis and elevated liver enzymes: A long-term follow-up of predictors, surveillance, and outcome in clinical practice. *Int J Rheum Dis*. 2019 Jul;22(7):1226-1232.
52. Morth C, Valachis A, Abu Sabaa A, Marshall K, Hedstrom G, Flogegard M, Baecklund E, Enblad G. Autoimmune disease in patients with diffuse large B-cell lymphoma: occurrence and impact on outcome. *Acta Oncol*. 2019 Aug;58(8):1170-1177.
53. Tessier-Cloutier B, Twa DD, Baecklund E, Gascoyne R, Johnson NA, Backlin C, Kamen DL, Clarke AE, Ramsey-Goldman R, Lee JL, Farinha P, Bernatsky S. Cell of origin in diffuse large B-cell lymphoma in systemic lupus erythematosus: molecular and clinical factors associated with survival. *Lupus Sci Med*. 2019 May 4;6(1):e000324.

54. Hellbacher E, Hjorton K, Backlin C, Enblad G, Sundstrom C, Baecklund E, Knight A. Malignant lymphoma in granulomatosis with polyangiitis: subtypes, clinical characteristics and prognosis. *Acta Oncol.* 2019 Aug 13;1-5.
55. Mofors J, Bjork A, Smedby KE, Kvarnstrom M, Forsblad-d'Elia H, Magnusson-Bucher S, Eriksson P, Mandl T, Baecklund E, Nordmark G, Wahren-Herlenius M. Increased risk of multiple myeloma in primary Sjogren's syndrome is limited to individuals with Ro/SSA and La/SSB autoantibodies. *Ann Rheum Dis.* 2020 Feb;79(2):307-308.
56. Sundbaum JK, Baecklund E, Eriksson N, Hallberg P, Kohnke H, Wadelius M. MTHFR, TYMS and SLC01B1 polymorphisms and adverse liver effects of methotrexate in rheumatoid arthritis. *Pharmacogenomics.* 2020 Apr;21(5):337-346.
57. Vasaitis L, Nordmark G, Theander E, Backlin C, Smedby KE, Askling J, Ronnblom L, Sundstrom C, Baecklund E. Population-based study of patients with primary Sjogren's syndrome and lymphoma: lymphoma subtypes, clinical characteristics, and gender differences. *Scand J Rheumatol.* 2020 May;49(3):225-232.
58. Hellgren K, Di Giuseppe D, Smedby KE, Sundstrom C, Askling J, Baecklund E. Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtype. *Rheumatology (Oxford).* 2021 Feb 1;60(2):809-819.
59. Hetland ML, Haavardsholm EA, Rudin A, Nordstrom D, Nurmohamed M, Gudbjornsson B, Lampa J, Horslev-Petersen K, Uhlig T, Grondal G, Ostergaard M, Heiberg MS, Twisk J, Lend K, Krabbe S, Hyldstrup LH, Lindqvist J, Hultgard Ekwall AK, Gron KL, Kapetanovic M, Faustini F, Tuompo R, Lorenzen T, Cagnotto G, Baecklund E, Hendricks O, Vedder D, Sokka-Isler T, Husmark T, Ljosa MA, Brodin E, Ellingsen T, Soderbergh A, Rizk M, Olsson AR, Larsson P, Uhrenholt L, Just SA, Stevens DJ, Laurberg TB, Bakland G, Olsen IC, van Vollenhoven R; NORD-STAR study group. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial. *BMJ.* 2020 Dec 2;371:m4328.
60. Thorlacius GE, Hultin-Rosenberg L, Sandling JK, Bianchi M, Imgenberg-Kreuz J, Pucholt P, Theander E, Kvarnstrom M, Forsblad-d'Elia H, Bucher SM, Norheim KB, Johnsen SJA, Hammenfors D, Skarstein K, Jonsson MV, Baecklund E, Aqrabi LA, Jensen JL, Palm O, Morris AP; DISSECT consortium; the ImmunoArray consortium, Meadows JRS, Rantapaa-Dahlqvist S, Mandl T, Eriksson P, Lind L, Omdal R, Jonsson R, Lindblad-Toh K, Ronnblom L, Wahren-Herlenius M, Nordmark G. Genetic and clinical basis for two distinct subtypes of primary Sjogren's syndrome. *Rheumatology (Oxford).* 2021 Feb 1;60(2):837-848.
61. Bywall KS, Kihlbom U, Hansson M, Falahee M, Raza K, Baecklund E, Veldwijk J. Patient preferences on rheumatoid arthritis second-line treatment: a discrete choice experiment of Swedish patients. *Arthritis Res Ther.* 2020 Dec 19;22(1):288.
62. Bower H, Frisell T, Di Giuseppe D, Delcoigne B, Ahlenius GM, Baecklund E, Chatzidionysiou K, Feltelius N, Forsblad-d'Elia H, Kastbom A, Klareskog L, Lindqvist E, Lindstrom U, Turesson C, Sjowall C, Askling J; ARTIS Study Group. Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. *Ann Rheum Dis.* 2021 Feb 23;80(8):1086-93.
63. Bywall KS, Veldwijk J, Hansson MG, Baecklund E, Raza K, Falahee M, Kihlbom U. Does being exposed to an educational tool influence patient preferences? The influence of an educational tool on patient preferences assessed by a discrete choice experiment. *Patient Educ Couns.* 2021 Oct;104(10):2577-2585.
64. Kinch A, Baecklund E, Molin D, Pauksens K, Sundstrom C, Tufveson G, Enblad G. Prior antithymocyte globulin therapy and survival in post-transplant lymphoproliferative disorders. *Acta Oncol.* 2021 Jun;60(6):771-778.
65. Karlsson Sundbaum J, Arkema EV, Bruchfeld J, Jonsson J, Askling J, Baecklund E. Tuberculosis in biologic-naive patients with rheumatoid arthritis - risk factors and tuberculosis characteristics. *J Rheumatol.* 2021 Aug;48(8):1243-1250.
66. Sundbaum JK, Baecklund E, Eriksson N, Kohnke H, Wallenberg M, Cavalli M, Wadelius C, Wadelius M, Hallberg P. Genome-wide association study of liver enzyme elevation in rheumatoid arthritis patients starting methotrexate. *Pharmacogenomics* 2021 Oct;22(15):973-982.
67. Sima A, Hollander P, Baecklund E, Smedby KE, Enblad G, Amini RM. Superior outcome for splenectomised patients in a population-based study of splenic marginal zone lymphoma in Sweden. *Br J Haematol.* 2021 Aug;194(3):568-579.
68. Bower H, Frisell T, di Giuseppe D, Delcoigne B, Ahlenius GM, Baecklund E, Chatzidionysiou K, Feltelius N, Forsblad-d'Elia H, Kastbom A, Klareskog L, Lindqvist E, Lindstrom U, Turesson C,

Sjowall C, Askling J; ARTIS Study Group. Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision. *RMD Open*. 2021 Dec;7(3):e001987.

69. Lundtoft C, Pucholt P, Martin M, Bianchi M, Lundstrom E, Eloranta ML, Sandling JK, Sjowall C, Jonsen A, Gunnarsson I, Rantapaa-Dahlqvist S, Bengtsson AA, Leonard D, Baecklund E, Jonsson R, Hammenfors D, Forsblad-d'Elia H, Eriksson P, Mandl T, Bucher SM, Norheim KB, Johnsen SJA, Omdal R, Kvarnstrom M, Wahren-Herlenius M, Notarnicola A, Andersson H, Molberg O, Diederichsen LP, Almlof J, Syvanen AC, Kozyrev SV, Lindblad-Toh K; DISSECT consortium; ImmunoArray consortium, Nilsson B, Blom AM, Lundberg IE, Nordmark G, Diaz-Gallo LM, Svenungsson E, Ronnblom L. Complement C4 copy number variation is linked to SSA/Ro and SSB/La autoantibodies in systemic inflammatory autoimmune diseases. *Arthritis Rheumatol*. 2022 Mar 21. doi: 10.1002/art.42122.

70. Hellbacher E, Sundstrom C, Molin D, Baecklund E, Hollander P. *Cancers (Basel)*. Expression of PD-1, PD-L1 and PD-L2 in Lymphomas in Patients with Pre-Existing Rheumatic Diseases-A Possible Association with High Rheumatoid Arthritis Disease Activity. 2022 Mar 15;14(6):1509.

71. Khatri B, Tessneer KL, Rasmussen A, Aghakhanian F, Reksten TR, Adler A, Alevizos I, Anaya JM, Aqrabi LA, Baecklund E, Brun JG, Bucher SM, Eloranta ML, Engelke F, Forsblad-d'Elia H, Glenn SB, Hammenfors D, Imgenberg-Kreuz J, Jensen JL, Johnsen SJA, Jonsson MV, Kvarnstrom M, Kelly JA, Li H, Mandl T, Martin J, Nocturne G, Norheim KB, Palm O, Skarstein K, Stolarczyk AM, Taylor KE, Teruel M, Theander E, Venuturupalli S, Wallace DJ, Grundahl KM, Hefner KS, Radfar L, Lewis DM, Stone DU, Kaufman CE, Brennan MT, Guthridge JM, James JA, Scofield RH, Gaffney PM, Criswell LA, Jonsson R, Eriksson P, Bowman SJ, Omdal R, Ronnblom L, Warner B, Rischmueller M, Witte T, Farris AD, Mariette X, Alarcon-Riquelme ME; PRECISESADS Clinical Consortium, Shiboski CH; Sjogren's International Collaborative Clinical Alliance (SICCA), Wahren-Herlenius M, Ng WF; UK Primary Sjogren's Syndrome Registry, Sivils KL, Adrianto I, Nordmark G, Lessard CJ. Genome-wide association study identifies Sjogren's risk loci with functional implications in immune and glandular cells. *Nat Commun*. 2022 Jul 27;13(1):4287.

72. Lundtoft C, Sjowall C, Rantapaa-Dahlqvist S, Bengtsson AA, Jonsen A, Pucholt P, Wu YL, Lundstrom E, Eloranta ML, Gunnarsson I, Baecklund E, Jonsson R, Hammenfors D, Forsblad-d'Elia H, Eriksson P, Mandl T, Bucher S, Norheim KB, Johnsen SJA, Omdal R, Kvarnstrom M, Wahren-Herlenius M, Truedsson L, Nilsson B, Kozyrev SV, Bianchi M, Lindblad-Toh K; DISSECT consortium; ImmunoArray consortium, Yu CY, Nordmark G, Sandling JK, Svenungsson E, Leonard D, Ronnblom L. Combined genetic deficiencies of the classical complement pathway are strongly associated with both systemic lupus erythematosus and primary Sjogren's syndrome. *Arthritis Rheumatol*. 2022 Jun 21.

73. Saevarsdottir S, Stefansdottir L, Sulem P, Thorleifsson G, Ferkingstad E, Rutsdottir G, Glintborg B, Westerlind H, Grondal G, Loft IC, Sorensen SB, Lie BA, Brink M, Arlestig L, Arnthorsson AO, Baecklund E, Banasik K, Bank S, Bjorkman LI, Ellingsen T, Erikstrup C, Frei O, Gjerdtsson I, Gudbjartsson DF, Gudjonsson SA, Halldorsson GH, Hendricks O, Hillert J, Hogdall E, Jacobsen S, Jensen DV, Jonsson H, Kastbom A, Kockum I, Kristensen S, Kristjansdottir H, Larsen MH, Linauskas A, Hauge EM, Loft AG, Ludviksson BR, Lund SH, Markusson T, Masson G, Melsted P, Moore KHS, Munk H, Nielsen KR, Norddahl GL, Oddsson A, Olafsdottir TA, Olason PI, Olsson T, Ostrowski SR, Horslev-Petersen K, Rognvaldsson S, Sanner H, Silberberg GN, Stefansson H, Sorensen E, Sorensen IJ, Turesson C, Bergman T, Alfredsson L, Kvien TK, Brunak S, Steinsson K, Andersen V, Andreassen OA, Rantapaa-Dahlqvist S, Hetland ML, Klareskog L, Askling J, Padyukov L, Pedersen OB, Thorsteinsdottir U, Jonsdottir I, Stefansson K; Members of the DBDS Genomic Consortium; Danish RA Genetics Working Group; Swedish Rheumatology Quality Register Biobank Study Group (SRQb). Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset.

*Ann Rheum Dis*. 2022 Aug;81(8):1085-1095.

Other:

Chapter "Reumatisk sjukdom och malignitet" in textbook "Reumatologi", red Klarskog L, Saxne T, Studentlitteratur 2005. Revisions 2011 and 2017.

Theander E, Baecklund E. Sjogren's syndrome and cancer. *Sjogren's syndrome handbook*, Sjogren's syndrome Foundation, 2011.

Baecklund E, Theander E. Sjogren's syndrome and lymphoma. *Sjogren Syndrome Book*, Springer, red Ramos-Casals, Stone and Moutsopoulos, 2012.

Other publications indexed in Pub Med (Eva Baecklund member of study groups)

1. Naranjo A, Sokka T, Descalzo MA, Calvo-Alen J, Horslev-Petersen K, Luukkainen RK, Combe B, Burmester GR, Devlin J, Ferraccioli G, Morelli A, Hoekstra M, Majdan M, Sadkiewicz S, Belmonte M, Holmqvist AC, Choy E, Tunc R, Dimic A, Bergman M, Toloza S, Pincus T; QUEST-RA Group. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. *Arthritis Res Ther.* 2008;10(2):R30.
2. Sokka T, Hetland ML, Makinen H, Kautiainen H, Horslev-Petersen K, Luukkainen RK, Combe B, Badsha H, Drosos AA, Devlin J, Ferraccioli G, Morelli A, Hoekstra M, Majdan M, Sadkiewicz S, Belmonte M, Holmqvist AC, Choy E, Burmester GR, Tunc R, Dimic A, Nedovic J, Stankovic A, Bergman M, Toloza S, Pincus T; Questionnaires in Standard Monitoring of Patients With Rheumatoid Arthritis Group. Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. *Arthritis Rheum.* 2008 Sep;58(9):2642-51.
3. Sokka T, Toloza S, Cutolo M, Kautiainen H, Makinen H, Gogus F, Skacic V, Badsha H, Peets T, Baranauskaite A, Geher P, Ujfalusy I, Skopouli FN, Mavrommati M, Alten R, Pohl C, Sibilia J, Stancati A, Salaffi F, Romanowski W, Zarowny-Wierzbinska D, Henrohn D, Bresnihan B, Minnock P, Knudsen LS, Jacobs JW, Calvo-Alen J, Lazovskis J, Pinheiro Gda R, Karateev D, Andersone D, Rexhepi S, Yazici Y, Pincus T; QUEST-RA Group. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. *Arthritis Res Ther.* 2009;11(1):R7.
4. Bergsten U, Bergman S, Fridlund B, Alfredsson L, Berglund A, Petersson IF, Arvidsson B; EIRA Study Group. Patients' conceptions of the cause of their rheumatoid arthritis: a qualitative study. *Musculoskeletal Care.* 2009 Dec;7(4):243-55.
5. Rosell M, Wesley AM, Rydin K, Klareskog L, Alfredsson L; EIRA study group. Dietary fish and fish oil and the risk of rheumatoid arthritis. *Epidemiology.* 2009 Nov;20(6):896-901.
6. Stolt P, Yahya A, Bengtsson C, Kallberg H, Ronnelid J, Lundberg I, Klareskog L, Alfredsson L; EIRA Study Group. Silica exposure among male current smokers is associated with a high risk of developing ACPA-positive rheumatoid arthritis. *Ann Rheum Dis.* 2010 Jun;69(6):1072-6.
7. Jawaheer D, Olsen J, Lahiff M, Forsberg S, Lahteenmaki J, da Silveira IG, Rocha FA, Magalhaes Laurindo IM, Henrique da Mota LM, Drosos AA, Murphy E, Sheehy C, Quirke E, Cutolo M, Rexhepi S, Dadoniene J, Verstappen SM, Sokka T; QUEST-RA. Gender, body mass index and rheumatoid arthritis disease activity: results from the QUEST-RA Study. *Clin Exp Rheumatol.* 2010 Jul-Aug;28(4):454-61.
8. Neovius M, Sundstrom A, Simard J, Wettermark B, Cars T, Feltelius N, Askling J, Klareskog L; ARTIS Study Group. Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009. *Scand J Rheumatol.* 2011 Jan;40(1):8-15.
9. Neovius M, Simard J, Sundstrom A, Jacobsson L, Geborek P, Saxne T, Feltelius N, Klareskog L, Askling J; ARTIS Study Group. Generalisability of clinical registers used for drug safety and comparative effectiveness research: coverage of the Swedish Biologics Register. *Ann Rheum Dis.* 2011 Mar;70(3):516-9.
10. Neovius M, Simard JF, Askling J; ARTIS study group. Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden. *Ann Rheum Dis.* 2011 Apr;70(4):624-9.
11. Kallberg H, Ding B, Padyukov L, Bengtsson C, Ronnelid J, Klareskog L, Alfredsson L; EIRA Study Group. Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoking. *Ann Rheum Dis.* 2011 Mar;70(3):508-11.
12. Neovius M, Simard JF, Klareskog L, Askling J; ARTIS Study Group. Sick leave and disability pension before and after initiation of antirheumatic therapies in clinical practice. *Ann Rheum Dis.* 2011 Aug;70(8):1407-14.
13. Neovius M, Simard JF, Askling J; ARTIS Study Group. How large are the productivity losses in contemporary patients with RA, and how soon in relation to diagnosis do they develop? *Ann Rheum Dis.* 2011 Jun;70(6):1010-5.
14. Raaschou P, Simard JF, Neovius M, Askling J; Anti-Rheumatic Therapy in Sweden Study Group. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents. *Arthritis Rheum.* 2011 Jul;63(7):1812-22.
15. Sverdrup BM, Kallberg H, Klareskog L, Alfredsson L; Epidemiological Investigation of Rheumatoid Arthritis Study Group. Usage of skin care products and risk of rheumatoid arthritis:

results from the Swedish EIRA study. *Arthritis Res Ther.* 2012 Feb 28;14(1):R41.

16. Arkema EV, van Vollenhoven RF, Askling J; ARTIS Study Group. Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study. *Ann Rheum Dis.* 2012 Nov;71(11):1865-7.
17. Simard JF, Neovius M, Askling J; ARTIS Study Group. Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: drug-specific comparisons in the Swedish Biologics Register. *Arthritis Rheum.* 2012 Nov;64(11):3502-10.
18. Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, Klearman M, Musselman D, Agarwal S, Green J, Kavanaugh A; ADACTA Study Investigators. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. *Lancet.* 2013 May 4;381(9877):1541-50.
19. Raaschou P, Simard JF, Holmqvist M, Askling J; ARTIS Study Group. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. *BMJ.* 2013 Apr 8;346:f1939.
20. Chatzidionysiou K, Askling J, Eriksson J, Kristensen LE, van Vollenhoven R; for the ARTIS group. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. *Ann Rheum Dis.* 2015 May;74(5):890-6.
21. Arkema EV, Feltelius N, Olsson T, Askling J; on behalf of the ARTIS study group; on behalf of the ARTIS study group. No association between rheumatoid arthritis, amyotrophic lateral sclerosis, and tumour necrosis factor inhibitor treatment. *Ann Rheum Dis.* 2014 Nov;73(11):2061-2.
22. Raaschou P, Frisell T, Askling J; for the ARTIS Study Group; for the ARTIS Study Group. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study. *Ann Rheum Dis.* 2015 Dec;74(12):2137-43.
23. Wadstrom H, Eriksson JK, Neovius M, Askling J; ARTIS Study Group How good is the coverage and how accurate are exposure data in the Swedish Biologics Register (ARTIS)? *Scand J Rheumatol.* 2015;44(1):22-8.
  
24. Lie E, Kristensen LE, Forsblad-d'Elia H, Zverkova-Sandstrom T, Askling J, Jacobsson LT; ARTIS Study Group. The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study. *Ann Rheum Dis.* 2015 Jun;74(6):970-8.
25. Chatzidionysiou K, Kristensen LE, Eriksson J, Askling J, van Vollenhoven R; ARTIS Group. Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register. *Scand J Rheumatol.* 2015;44(6):431-7.
26. Raaschou P, Simard JF, Asker Hagelberg C, Askling J; ARTIS Study Group. Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden. *BMJ.* 2016 Jan 28;352:i262.
27. Wadstrom H, Frisell T, Sparen P, Askling J; ARTIS study group. Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden. *Ann Rheum Dis.* 2016 Jul;75(7):1272-8.
28. Ljung L, Rantapaa-Dahlqvist S, Jacobsson LT, Askling J; ARTIS Study Group. Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis. *Ann Rheum Dis.* 2016 Dec;75(12):2087-2094.
29. Hellgren K, Dreyer L, Arkema EV, Glinborg B, Jacobsson LT, Kristensen LE, Feltelius N, Hetland ML, Askling J; ARTIS Study Group, For the DANBIO Study Group. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers. *Ann Rheum Dis.* 2017 Jan;76(1):105-111.
30. Gron KL, Arkema EV, Glinborg B, Mehnert F, Ostergaard M, Dreyer L, Norgaard M, Krogh NS, Askling J, Hetland ML; ARTIS Study Group. Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden. *Ann Rheum Dis.* 2019 Mar;78(3):320-327.
31. Frisell T, Dehlin M, Di Giuseppe D, Feltelius N, Turesson C, Askling J; ARTIS Study Group. Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register. *Rheumatology (Oxford).* 2019 Jan 21. doi: 10.1093/rheumatology/key433. [Epub ahead of print]



32.Huss V, Bower H, Wadstrom H, Frisell T, Askling J; ARTIS group. Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice. *Rheumatology (Oxford)*. 2022 May 5;61(5):1810-1818.  
Uppsala 2022-07-31/Eva Baecklund

**Projects** I have been involved in an number of projects focused on rheumatic diseases and malignancy risks including potential associations with treatments.

I am since 2011 and currently PI of the AUTO-LYMPHOMA study, a Swedish national prospective academic study including patients with rheumatic disease who develop malignant lymphoma, and am supervisor of two PhD-students involved in the study.

I have been a member of ARTIS (Anti-rheumatic therapy in Sweden) since its start. This is a study group within the Swedish Rheumatism Association with a number of projects and publications in the area of drug safety.

Investigator in clinical trials

RISK, TRIC - ASA, heparin in myocardial infarction 1988-90

Nordic Myeloma study 1990-91

Consensus II - ACE-inhibitors in myocardial infarction 1990-91

FA31A in rheumatoid arthritis 1995-96

Etanercept in rheumatoid arthritis 1998-2003

Comet: Etanercept/methotrexate in early rheumatoid arthritis 2005-2008

Serene: Mabthera/methotrexate in rheumatoid arthritis 2006-2011

Optima: Adalimumab/methotrexate in early rheumatoid arthritis 2007-2011

SCRIPT: Ocrelizumab in rheumatoid arthritis 2008-2009

JAK 3 in rheumatoid arthritis 2010-2013

ADACTA: Tocilizumab/adalimumab in rheumatoid arthritis 2011-2012

NORDSTAR: An academic study of treatment in early RA, member of Swedish steering committee and investigator at site Uppsala 2013-

.

**Memberships**

- Member of the group developing national guidelines for the treatment of RA for the Swedish Society for Rheumatology
- Member and PI of the group developing national guidelines regarding drug safety for the Swedish Society for Rheumatology
- Member of the steering group for ARTIS, the Swedish Biologics Register (pi Johan Askling)
- Member of the Swedish Rheumatology Quality Register (SRQ) Biobanking Committee
- Member of an expert group which developed National guidelines for RA for the Swedish National Board of Health and Welfare
- Expert in a group developing guidelines for prophylactic use of antibiotics in dental care for the Swedish Medical Agency 2012
- Member in formal scientific networks (all finished at the latest 2021)
  - Uppsala Hematology Network (pi prof Richard Rosenquist)
  - Lymphoproliferative diseases Network (international network, pi prof Richard Rosenquist)
  - Swedish-Norwegian Sjogren Network (pi Gunnel Nordmark)
  - Epidemiologic investigation of risk factors for rheumatoid arthritis (EIRA) (pi prof Lars Alfredsson)
  - Quest-RA (pi Tuulikki Sokka-Isler)
- Member of
  - Swedish Society for Rheumatology (Svenska Reumatologforeningen)
  - Swedish Society for Senior Physicians (Svenska Overlakarforeningen)
  - Swedish Society for Physicians (Svenska Lakarsallskapet)

**Other Relevant Information**

- Dissertation/PhD degree Faculty of Medicine (rheumatology), Uppsala University 2005 - Name of thesis: Associations between rheumatoid arthritis and malignant lymphomas - Opponent: Professor Tore Kvien, Diakjonhemets Hospital, Oslo, Norway

Supervisor PhD students:

Main supervisor: 3 (Lilian Vasaitis (Sjogren's syndrome and lymphoma), Johanna Sundbaum (drug safety in rheumatic diseases) , Erik Hellbacher (rheumatic diseases and hematological malignancies)

Co-supervisor: 5

- Investigator in clinical trials

RISK, TRIC - ASA, heparin in myocardial infarction 1988-90

Nordic Myeloma study 1990-91

Consensus II - ACE-inhibitors in myocardial infarction 1990-91

FA31A in rheumatoid arthritis 1995-96

Etanercept in rheumatoid arthritis 1998-2003

Comet: Etanercept/methotrexate in early rheumatoid arthritis 2005-2008

Serene: Mabthera/methotrexate in rheumatoid arthritis 2006-2011

Optima: Adalimumab/methotrexate in early rheumatoid arthritis 2007-2011

SCRIPT: Ocrelizumab in rheumatoid arthritis 2008-2009

JAK 3 in rheumatoid arthritis 2010-2013

ADACTA: Tocilizumab/adalimumab in rheumatoid arthritis 2011-2012

NORDSTAR: An academic study of treatment in early RA, member of Swedish steering committee and investigator at site Uppsala 2013-